Sarah leads the policy and access expertise across the EU and Emerging Markets for Chandler Chicco Companies (CCC). Throughout her nine years in healthcare, Sarah has led impressive change programmes with enduring legacies across academia, health service provision and healthcare education and communications. Her five-year career at CCC has encompassed founding roles across three companies and evolved the organisation’s service offer to include strength in engaging and collaborating with access and policy stakeholders. Sarah’s expertise is built on her biochemistry background, post-graduate studies in healthcare management, policy and health economics and experience within health service in quality, service design, guideline development and patient group-provider strategy. This experience, coupled with her passion to improve outcomes through collaborative working drives her ability to ensure mutual benefits are realised across stakeholders.
Making healthcare more accessible and affordable for the public is a prominent focus of the Chinese government’s current health reform efforts – a focus that will not alter despite the recent transition in leadership at the central government level. Achieving this mandate requires stringent cost-control measures, most notably in the form of harsh national drug price cuts and restricted access to innovative therapies. This environment creates for industry an opportunity to ensure patients have access to the right care at the right time by aligning business, marketing and sales strategies with government reform priorities. It also demonstrates the need to communicate clearly about the broader value of innovative therapies to gain optimal access as cost-pressures increase and competition intensifies. Today it is about how we can better integrate and work together to facilitate access to services, access to medicines across a broader geography and, importantly, access to valuable information and education on health and medical care. Access should be a central objective around which all departments and functions rally. Integrate departments around this objective and look to develop real customer-centric targeting and an understanding of the broader needs of the payer audience plus their perspective on managing health outcomes withinContinue Reading
“Market access” continues to be a subject of much discussion among the industry. Across the globe, we see governments scrambling to implement increasingly sophisticated cost-control measures to manage the expanding health demands of their population. Despite its booming economy and appetite for growth, China too faces the challenge of creating sustainable healthcare and access to medicines for its population – not an easy task with a population of over 1.3 billion people spread across diverse geographies with massive disparities in access to care. The Chinese government will invest $125 billion over the next three years to expand access to care – making “access” a central aim. Key focus areas for this reform include the Basic Medical Insurance System, National Essential Drugs List, public hospital reform, establishing primary care provision and improving basic healthcare through developing clear care pathways. As a dynamic and rapidly evolving market, China is keen to learn from others and has been working with the UK’s NICE to look at techniques for health technology assessment and development of clinical guidelines. There is a huge opportunity for industry to collaborate with the increasing pool of Chinese healthcare stakeholders to help shape clear care pathways and enable faster accessContinue Reading